Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab ravtansine + PLD in Platinum-Resistant Ovarian Cancer
NCT02751918Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2016
- Primary completion
- Aug 2019
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of anetumab ravtansine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose at 6 months and Incidence of serious and non-serious adverse events at 6 months. Started Jun 2016; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02751918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751918.